Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (81-90 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy|October 13, 2010
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patientsJosé Moltó, Marta Valle, David Back, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World CohortChristoph Höner Zu Siederdissen, Benjamin Maasoumy, Fiona Marra, et al.
AIDS (London, England)|June 23, 2006
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersAlan Winston, David Back, Carl Fletcher, et al.
AIDS (London, England)|May 31, 2002
Therapeutic drug monitoring in HIV infection: current status and future directionsDavid Back, Giorgio Gatti, Courtney Fletcher, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 13, 2016
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasmaSujan Dilly Penchala, Sandra Fawcett, Laura Else, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individualsAkil Jackson, Victoria Watson, David Back, et al.
Pageof 15

Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy|October 13, 2010
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patientsJosé Moltó, Marta Valle, David Back, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World CohortChristoph Höner Zu Siederdissen, Benjamin Maasoumy, Fiona Marra, et al.
AIDS (London, England)|June 23, 2006
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersAlan Winston, David Back, Carl Fletcher, et al.
AIDS (London, England)|May 31, 2002
Therapeutic drug monitoring in HIV infection: current status and future directionsDavid Back, Giorgio Gatti, Courtney Fletcher, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 13, 2016
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasmaSujan Dilly Penchala, Sandra Fawcett, Laura Else, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individualsAkil Jackson, Victoria Watson, David Back, et al.
Pageof 15